Supernus Pharmaceuticals (SUPN) Return on Equity [ROE] (2012 - 2026)
Supernus Pharmaceuticals (SUPN) reported Return on Equity [ROE] of -8.08% for Q2 2026, down 14.24 percentage points from 6.16% a year earlier.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) Return on Equity [ROE] (2012 - 2026) Analysis & Trends
For FY2025, Supernus Pharmaceuticals posted Return on Equity [ROE] of -3.68%, down 11.22 percentage points from FY2024.
- Return on Equity [ROE] has a five-year change of -22.62 percentage points (FY2020 to FY2025).
- By year, Return on Equity [ROE] came in at 7.55% in FY2024 (+7.40 pp), 0.15% in FY2023 (-6.99 pp), 7.13% in FY2022 (+0.29 pp) and 6.85% in FY2021 (-12.10 pp).
- The Q2 2026 figure ranks as the lowest quarterly Return on Equity [ROE] since Q4 2014.
- Year over year, Return on Equity [ROE] gained in four of the last seven quarters, with an average year-over-year change of -1.33 percentage points.
- The high point for year-over-year Return on Equity [ROE] in five years was Q1 2025 (a gain of 7.67 percentage points); the low point was Q2 2026 (a drop of 14.24 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Supernus Pharmaceuticals | 2.47 Bn | 1.12 Bn | 185.39 Mn | -8.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.08% |
| Dec 31, 2025 | -3.65% |
| Sep 30, 2025 | -1.80% |
| Jun 30, 2025 | 6.16% |
| Mar 31, 2025 | 6.00% |
| Dec 31, 2024 | 7.23% |
| Sep 30, 2024 | 6.08% |
| Jun 30, 2024 | 0.55% |
| Mar 31, 2024 | -1.68% |
| Dec 31, 2023 | 0.14% |
| Sep 30, 2023 | 2.79% |
| Jun 30, 2023 | 4.73% |
| Mar 31, 2023 | 5.78% |
| Dec 31, 2022 | 6.98% |
| Sep 30, 2022 | 4.44% |
| Jun 30, 2022 | 6.88% |
| Mar 31, 2022 | 8.92% |
| Dec 31, 2021 | 6.57% |
| Sep 30, 2021 | 10.24% |
| Jun 30, 2021 | 13.01% |
API Access
Supernus Pharmaceuticals Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();